179 related articles for article (PubMed ID: 30481559)
41. Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): effect of drug loading and biopharmaceutical characterizations.
Jansook P; Pichayakorn W; Ritthidej GC
Drug Dev Ind Pharm; 2018 Oct; 44(10):1693-1700. PubMed ID: 29936874
[TBL] [Abstract][Full Text] [Related]
42. A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation.
Alak A; Moy S; Bekersky I
Ther Drug Monit; 1996 Oct; 18(5):604-9. PubMed ID: 8885127
[TBL] [Abstract][Full Text] [Related]
43. Stability and drug release studies of an antimycotic nanomedicine using HPLC, dynamic light scattering and atomic force microscopy.
Watanabe A; Takagi M; Murata S; Kato M
J Pharm Biomed Anal; 2018 Jan; 148():149-155. PubMed ID: 29028561
[TBL] [Abstract][Full Text] [Related]
44. Investigations on feasibility of in situ development of amphotericin B liposomes for industrial applications.
Singodia D; Verma A; Khare P; Dube A; Mitra K; Mishra PR
J Liposome Res; 2012 Mar; 22(1):8-17. PubMed ID: 21682670
[TBL] [Abstract][Full Text] [Related]
45. Amphotericin B formulations and drug targeting.
Torrado JJ; Espada R; Ballesteros MP; Torrado-Santiago S
J Pharm Sci; 2008 Jul; 97(7):2405-25. PubMed ID: 17893903
[TBL] [Abstract][Full Text] [Related]
46. [Utility and improvement of liposome injections AmBisome for clinical use].
Sugiyama I; Kudo K; Takahashi K; Sadzuka Y
Yakugaku Zasshi; 2010 Mar; 130(3):457-61. PubMed ID: 20190532
[TBL] [Abstract][Full Text] [Related]
47. Liposomal amphotericin B: clinical experience and perspectives.
Gibbs WJ; Drew RH; Perfect JR
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):167-81. PubMed ID: 15918775
[TBL] [Abstract][Full Text] [Related]
48. In vitro - in vivo relations for the parenteral liposomal formulation of Amphotericin B: A clinically relevant approach with PBPK modeling.
Díaz de León-Ortega R; D'Arcy DM; Lamprou DA; Fotaki N
Eur J Pharm Biopharm; 2020 Mar; ():177-187. PubMed ID: 32147578
[TBL] [Abstract][Full Text] [Related]
49. Circular dichroism study of interactions of Fungizone or AmBisome forms of amphotericin B with human low density lipoproteins.
Barwicz J; Beauregard M; Tancrède P
Biopolymers; 2002; 67(1):49-55. PubMed ID: 11842413
[TBL] [Abstract][Full Text] [Related]
50. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
51. Nanosomal Amphotericin B is an efficacious alternative to Ambisome for fungal therapy.
Sheikh S; Ali SM; Ahmad MU; Ahmad A; Mushtaq M; Paithankar M; Mandal J; Saptarishi D; Sehgal A; Maheshwari K; Ahmad I
Int J Pharm; 2010 Sep; 397(1-2):103-8. PubMed ID: 20621173
[TBL] [Abstract][Full Text] [Related]
52. Design of Protease-Responsive Antifungal Liposomal Formulation Decorated with a Lipid-Modified Chitin-Binding Domain.
Saputra H; Safaat M; Santoso P; Wakabayashi R; Goto M; Taira T; Kamiya N
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612381
[No Abstract] [Full Text] [Related]
53. Physicochemical properties of amphotericin B liposomes prepared by reverse-phase evaporation method.
Rojanapanthu P; Sarisuta N; Chaturon K; Kraisintu K
Drug Dev Ind Pharm; 2003 Jan; 29(1):31-7. PubMed ID: 12602490
[TBL] [Abstract][Full Text] [Related]
54. Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection.
Bodhe PV; Kotwani RN; Kirodian BG; Kshirsagar NA; Pandya SK
J Assoc Physicians India; 2002 May; 50(5):662-70. PubMed ID: 12186120
[TBL] [Abstract][Full Text] [Related]
55. Physicochemical surrogates for in vitro toxicity assessment of liposomal amphotericin B.
Marx R; Lee J; Svirkin Y; Yoon S; Landrau N; Abul Kaisar M; Qin B; Park JH; Alam K; Kozak D; Wang Y; Xu X; Zheng J; Rivnay B
Int J Pharm; 2022 Nov; 628():122273. PubMed ID: 36228881
[TBL] [Abstract][Full Text] [Related]
56. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G
Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510
[TBL] [Abstract][Full Text] [Related]
57. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B.
Ahmad I; Sarkar AK; Bachhawat BK
Indian J Biochem Biophys; 1989 Dec; 26(6):351-6. PubMed ID: 2698855
[TBL] [Abstract][Full Text] [Related]
58. Enhanced stability and permeation potential of nanoemulsion containing sefsol-218 oil for topical delivery of amphotericin B.
Hussain A; Samad A; Singh SK; Ahsan MN; Faruk A; Ahmed FJ
Drug Dev Ind Pharm; 2015 May; 41(5):780-90. PubMed ID: 24654936
[TBL] [Abstract][Full Text] [Related]
59. Lipid-based antifungal agents: a concise overview.
Arikan S
Cell Mol Biol Lett; 2002; 7(3):919-22. PubMed ID: 12378276
[TBL] [Abstract][Full Text] [Related]
60. Investigation and simulation of dissolution with concurrent degradation under healthy and hypoalbuminaemic simulated parenteral conditions- case example Amphotericin B.
Díaz de León-Ortega R; D'Arcy DM; Bolhuis A; Fotaki N
Eur J Pharm Biopharm; 2018 Jun; 127():423-431. PubMed ID: 29602019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
